LILRB1 and neoplasm: Drugs targeting MHCI/LILRB1 axis may promote anti-tumor immune response and play a synergistic role with drugs targeting CD47-SIRPA axis; CD24-SIGLEC10 [43] interaction blocks the cytoskeleton rearrangement required by macrophage phagocytosis and triggers the inhibitory signal transduction cascade.